Lack of consensus identifies important areas for future clinical research: Advanced Prostate Cancer Consensus Conference (APCCC) 2019 findings. Read more about Lack of consensus identifies important areas for future clinical research: Advanced Prostate Cancer Consensus Conference (APCCC) 2019 findings.
Long-term outcomes in patients with advanced melanoma who had initial stable disease with pembrolizumab in KEYNOTE-001 and KEYNOTE-006. Read more about Long-term outcomes in patients with advanced melanoma who had initial stable disease with pembrolizumab in KEYNOTE-001 and KEYNOTE-006.
Late-onset kidney failure in survivors of childhood cancer: a report from the Childhood Cancer Survivor Study. Read more about Late-onset kidney failure in survivors of childhood cancer: a report from the Childhood Cancer Survivor Study.
An open-label single-arm phase II study of regorafenib for the treatment of angiosarcoma. Read more about An open-label single-arm phase II study of regorafenib for the treatment of angiosarcoma.
Re-induction ipilimumab following acquired resistance to combination ipilimumab and anti-PD-1 therapy. Read more about Re-induction ipilimumab following acquired resistance to combination ipilimumab and anti-PD-1 therapy.
Evidence-based recommendations on categories for extent of resection in diffuse glioma. Read more about Evidence-based recommendations on categories for extent of resection in diffuse glioma.
Transplant rejections associated with immune checkpoint inhibitors: A pharmacovigilance study and systematic literature review. Read more about Transplant rejections associated with immune checkpoint inhibitors: A pharmacovigilance study and systematic literature review.
Long-term safety of pembrolizumab monotherapy and relationship with clinical outcome: A landmark analysis in patients with advanced melanoma. Read more about Long-term safety of pembrolizumab monotherapy and relationship with clinical outcome: A landmark analysis in patients with advanced melanoma.
Survivorship in immune therapy: Assessing toxicities, body composition and health-related quality of life among long-term survivors treated with antibodies to programmed death-1 receptor and its ligand. Read more about Survivorship in immune therapy: Assessing toxicities, body composition and health-related quality of life among long-term survivors treated with antibodies to programmed death-1 receptor and its ligand.
Increased reporting of fatal hepatitis associated with immune checkpoint inhibitors. Read more about Increased reporting of fatal hepatitis associated with immune checkpoint inhibitors.
